These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11333714)

  • 1. [Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients].
    Estrada V; de Villar N; Serrano-Ríos M
    Med Clin (Barc); 2001 Mar; 116(12):479. PubMed ID: 11333714
    [No Abstract]   [Full Text] [Related]  

  • 2. High incidence of nevirapine-associated rash in HIV-infected Chinese.
    Ho TT; Wong KH; Chan KC; Lee SS
    AIDS; 1998 Oct; 12(15):2082-3. PubMed ID: 9814883
    [No Abstract]   [Full Text] [Related]  

  • 3. Europe warned of side effects.
    AIDS Patient Care STDS; 2000 Jul; 14(7):395-6. PubMed ID: 10935057
    [No Abstract]   [Full Text] [Related]  

  • 4. Nevirapine-based fixed-dose combination ARVs.
    Meldrum J
    GMHC Treat Issues; 2003 May; 17(5):5-9. PubMed ID: 12846176
    [No Abstract]   [Full Text] [Related]  

  • 5. [Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].
    Lackmann GM; Schmidt B; Niehues T
    Hautarzt; 2003 Aug; 54(8):765-6. PubMed ID: 12942192
    [No Abstract]   [Full Text] [Related]  

  • 6. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
    Soriano V; Dona C; Barreiro P; González-Lahoz J
    AIDS; 2000 Jul; 14(11):1672-3. PubMed ID: 10983663
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors.
    Arranz-Caso JA; Gorgolas M; Estrada V; García-Diaz JD
    HIV Med; 2004 Mar; 5(2):128-9. PubMed ID: 15012654
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.
    Johnson S; Baraboutis JG
    JAMA; 2000 Dec; 284(21):2722-3. PubMed ID: 11105175
    [No Abstract]   [Full Text] [Related]  

  • 9. From the Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
    JAMA; 2001 Jan 24-31; 285(4):402-3. PubMed ID: 11263401
    [No Abstract]   [Full Text] [Related]  

  • 10. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
    Bourezane Y; Salard D; Hoen B; Vandel S; Drobacheff C; Laurent R
    Clin Infect Dis; 1998 Nov; 27(5):1321-2. PubMed ID: 9827291
    [No Abstract]   [Full Text] [Related]  

  • 11. Nevirapine in children.
    Proj Inf Perspect; 1998 Dec; (26):7. PubMed ID: 11366500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Exanthema in a patient infected with the human immunodeficiency virus after starting antiretroviral treatment].
    Palacios Muñoz R; Santos González J; Bosch García R; Márquez Solero M
    Rev Clin Esp; 2000 Nov; 200(11):635-6. PubMed ID: 11196597
    [No Abstract]   [Full Text] [Related]  

  • 13. Widespread vitiligo after erythroderma caused by nevirapine in a patient with AIDS.
    Ramírez-Hernández M; Sánchez-Sierra B; Martínez-Escribano JA
    Acta Derm Venereol; 2007; 87(5):442-3. PubMed ID: 17721659
    [No Abstract]   [Full Text] [Related]  

  • 14. Nevirapine (Viramune).
    Res Initiat Treat Action; 2000 Mar; 6(1):18-9. PubMed ID: 11708179
    [No Abstract]   [Full Text] [Related]  

  • 15. Nevirapine-induced Stevens-Johnson syndrome in a mother and son.
    Liechty CA; Solberg P; Mwima G; Were W; Weidle PJ; Mermin J
    AIDS; 2005 Jun; 19(9):993-4. PubMed ID: 15905686
    [No Abstract]   [Full Text] [Related]  

  • 16. Prednisolone does not prevent the occurrence of nevirapine-induced rashes.
    Rey D; Partisani M; Krantz V; Kempf G; Nicolle M; de Mautort E; Priester M; Bernard-Henry C; Lang JM
    AIDS; 1999 Nov; 13(16):2307. PubMed ID: 10563719
    [No Abstract]   [Full Text] [Related]  

  • 17. Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
    Mehta U; Maartens G
    Lancet Infect Dis; 2007 Nov; 7(11):733-8. PubMed ID: 17961859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nevirapine-induced resistance is a problem.
    S Afr Med J; 2004 May; 94(5):338. PubMed ID: 15211947
    [No Abstract]   [Full Text] [Related]  

  • 19. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].
    Tasias M; Ruiz S; Deig E; Pedrol E
    Enferm Infecc Microbiol Clin; 2011; 29(7):556-7. PubMed ID: 21565428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.